NCT07257666

Brief Summary

Pilot, single-center, non-randomized, parallel-group clinical study designed to assess whether intraoperative application of autologous platelet-rich fibrin (PRF) at the bone-patellar tendon-bone (BPTB) donor site reduces postoperative anterior knee sensory deficit after anterior cruciate ligament (ACL) reconstruction in competitively active male athletes. Planned enrollment is 53 participants allocated to a PRF cohort or a standard-care cohort. The primary outcome is the proportion of participants without anterior knee sensory deficit at 12 months post-surgery.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
53

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jan 2022

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 7, 2022

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 7, 2023

Completed
2.5 years until next milestone

Study Completion

Last participant's last visit for all outcomes

July 14, 2025

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

September 23, 2025

Completed
2 months until next milestone

First Posted

Study publicly available on registry

December 2, 2025

Completed
Last Updated

December 15, 2025

Status Verified

December 1, 2025

Enrollment Period

1 year

First QC Date

September 23, 2025

Last Update Submit

December 5, 2025

Conditions

Keywords

Platelet-Rich FibrinACL reconstructionBone-Patellar Tendon-Bone autograftAnterior Cruciate Ligament InjuryKnee SurgerySensory DeficitDonor Site Morbidity

Outcome Measures

Primary Outcomes (1)

  • Proportion of participants without anterior knee sensory deficit at the donor site

    Sensory function assessed over a predefined 9-point area lateral to the surgical scar; deficit coded as 1 if \>3 points are reported as "no or altered touch," otherwise 0. Assessment performed with eyes closed; contralateral knee used for reference if uncertain. Measure Type \& Units: Percentage of participants (%)

    12 months post-surgery

Secondary Outcomes (1)

  • International Knee Documentation Committee (IKDC) Subjective Knee Form score (0-100; higher scores indicate better function)

    Baseline, 4, 8, and 12 months post-surgery

Other Outcomes (1)

  • Lysholm Knee Scoring Scale (0-100; higher scores indicate better function)

    Baseline, 4, 8, 12 months after surgery

Study Arms (2)

PRF Group

Patients undergoing ACL reconstruction with a bone-patellar tendon-bone (BPTB) autograft, with platelet-rich fibrin (PRF) applied at the donor site (n=24)

Biological: Platelet-rich fibrin (PRF)

Control Group

Patients undergoing ACL reconstruction with a BPTB autograft, treated with standard closure without PRF (n=29)

Procedure: Standard Closure (Control)

Interventions

Autologous PRF prepared intraoperatively from patient's venous blood and applied at the donor site after graft harvesting.

Also known as: Autologous PRF
PRF Group

Conventional closure of the donor site without PRF application

Control Group

Eligibility Criteria

Age18 Years - 40 Years
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Patients undergoing ACL reconstruction with bone-patellar tendon-bone (BPTB) autograft at the University Clinical Center of Serbia

You may qualify if:

  • Age 18-40 years
  • Isolated anterior cruciate ligament rupture confirmed by MRI and clinical examination
  • Planned ACL reconstruction with BPTB autograft
  • Written informed consent provided

You may not qualify if:

  • Previous knee surgery on the affected knee
  • Associated ligament injuries requiring additional reconstruction
  • Significant cartilage damage (Outerbridge grade III-IV beyond donor site changes)
  • Systemic disease affecting wound healing (e.g., diabetes mellitus, autoimmune disease)
  • Active infection
  • Refusal or inability to provide informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Clinical Center of Serbia (UKCS)

Belgrade, 11000, Serbia

Location

Related Publications (2)

  • Shichman I, Baruchi D, Rachevsky G, Amzallag N, Brandstetter AS, Vidra M, Morag G. Bone filling decreases donor site morbidity after anterior cruciate ligament reconstruction with bone-patellar tendon-bone autografts. Arch Orthop Trauma Surg. 2023 May;143(5):2565-2572. doi: 10.1007/s00402-022-04572-5. Epub 2022 Aug 2.

    PMID: 35916963BACKGROUND
  • Milovanovic D, Kadija M, Gavrilovic D, Sreckovic S, Bilanovic M, Matic A, Vukman P. Sensory Deficit Following Anterior Cruciate Ligament Reconstruction with Bone-Patellar Tendon-Bone Autograft: Platelet-Rich Fibrin (PRF) Could Provide a Solution. Medicina (Kaunas). 2025 Dec 12;61(12):2202. doi: 10.3390/medicina61122202.

MeSH Terms

Conditions

Anterior Cruciate Ligament InjuriesKnee InjuriesSensation Disorders

Condition Hierarchy (Ancestors)

Leg InjuriesWounds and InjuriesNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator, University Clinical Center of Serbia, Docent, Faculty of Medicine, University of Belgrade

Study Record Dates

First Submitted

September 23, 2025

First Posted

December 2, 2025

Study Start

January 7, 2022

Primary Completion

January 7, 2023

Study Completion

July 14, 2025

Last Updated

December 15, 2025

Record last verified: 2025-12

Data Sharing

IPD Sharing
Will not share

Individual participant data (IPD) will not be shared due to privacy considerations and institutional regulations. Summary results will be published in peer-reviewed journals.

Available IPD Datasets

Informed Consent Form (Ethics Committee approval No.)Access

Locations